Claims for Patent: 9,981,041

Summary for Patent: 9,981,041

Title:	Ophthalmic lubricating spray
Abstract:	An ophthalmic composition for administration as a spray to the eye is provided. The ophthalmic composition comprises a lubricant comprising hydroxypropyl methylcellulose (HPMC), mineral oil, and sterile water. The ophthalmic composition is also configured as a delivery vehicle for administration of ophthalmic pharmaceuticals to the eye. A method of treating keratoconjunctivitis sicca by administering the ophthalmic composition is also provided.
Inventor(s):	Salzman; Ira Jason (Woodbury, NY)
Assignee:
Application Number:	15/244,617
Patent Claims:	1. An ophthalmic composition for administration in a spray to the eye, the ophthalmic composition consisting of: a therapeutic agent; and a liquid delivery vehicle, the liquid delivery vehicle consisting of hydroxypropyl methylcellulose (HPMC) in an amount of about 0.2% w/w, mineral oil in an amount of about 20% w/w, and sterile water in an amount of about 79.8% w/w. 2. An ophthalmic composition according to claim 1, wherein the ophthalmic composition is one-part therapeutic agent to two parts liquid delivery vehicle. 3. An ophthalmic composition according to claim 1, wherein the therapeutic agent is selected from the group consisting of a steroid, an antimicrobial, a cytokine inhibitor, an antihistamine, NSAIDS, leukotriene inhibitors or a combination thereof. 4. An ophthalmic composition according to claim 1, wherein the therapeutic agent is selected from the group consisting of a steroid comprising cyclosporine or a combination of loteprednol etabonate or dexamethasone and tobramycin. 5. An ophthalmic composition according to claim 1, wherein the therapeutic agent consists of cyclosporine. 6. An ophthalmic composition according to claim 1, wherein the therapeutic agent is loteprednol etabonate at 0.5% w/w and tobramycin at 0.3% w/w. 7. An ophthalmic composition according to claim 1, wherein the therapeutic agent is cyclosporine at 0.05% w/w. 8. A method of treating an ophthalmic condition in a patient suffering therefrom, the method comprising: administering an effective amount of an ophthalmic composition in a spray consisting of a lubricant consisting of hydroxypropyl methylcellulose (HPMC) in an amount of about 0.2% w/w, mineral oil in an amount of about 20% w/w, and sterile water in an amount of about 79.8% w/w to an eye of the patient, and the ophthalmic condition is keratoconjunctivitis sicca. 9. A method according to claim 8, wherein the spray is dispensed in an aerosol bottle or a non-aerosol bottle that administers the ophthalmic composition to the eye via a spray plume. 10. A method according to claim 8, wherein 0.15 ml of the ophthalmic composition is administered to the eye.

Details for Patent 9,981,041

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2039-09-22